News US regulators reject Akcea and Ionis rare disease drug The US Food and Drug Administration (FDA) rejected Akcea and Ionis’ application for the use of Waylivra in treatment of familial chylomicronemia syndrome (FCS) despite earlier support of ex
News AZ grabs licence as Ionis NASH drug heads to the clinic Could antisense drug be a fatty liver disease blockbuster?
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Roche takes on development of potential Huntington’s breakth... Ionis has completed its licensing agreement with Roche for IONIS-HTTRx, a drug which could be a breakthrough in treating Huntington’s disease.
News Alnylam soars after drug success, paving way for RNAi era Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.
News Ionis to file rare disease drug after GSK declines option Firm turns down options for inotersen and IONIS-FB-LRX.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.